11 August 2021 : Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu1ABCDEF, Yu Zhang1BC, Meng Wang1BC, Zhenfa Zhang1BC, Dongsheng Yue1BC, Shichang Liu2BC, Yi Pan3BC, Changli Wang1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 5 Survival of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
| Variable | ITT (n=36) | Surgery (n=23) |
|---|---|---|
| OS (month), median (95% CI) | 31.4 (19.0-NE) | 45.0 (22.6-NE) |
| 1-year OS rate, % (95% CI) | 85.8 (69.1–93.8) | 95.7 (72.9–99.4) |
| 3-year OS rate, % (95% CI) | 42.2 (23.8–59.6) | 52.6 (26.6–73.2) |
| PFS (month), median (95% CI) | 19.0 (11.6–43.6) | 31.4 (10.4-NE) |
| 1-year PFS rate, % (95% CI) | 68.1 (49.8–80.9) | 67.1 (43.1–82.8) |
| 3-year PFS rate, % (95% CI) | 38.3 (21.5–54.9) | 45.8 (23.2–65.8) |
| CI – confidence interval; ITT – intention-to-treat; NA – not applicable; NE – not evaluated; OS – overall survival; PFS – progression-free survival. | ||